CY1124564T1 - Εξασθενημενης λοιμογονικοτητας βακτηριδια για θεραπεια κακοηθων συμπαγων ογκων - Google Patents
Εξασθενημενης λοιμογονικοτητας βακτηριδια για θεραπεια κακοηθων συμπαγων ογκωνInfo
- Publication number
- CY1124564T1 CY1124564T1 CY20211100666T CY211100666T CY1124564T1 CY 1124564 T1 CY1124564 T1 CY 1124564T1 CY 20211100666 T CY20211100666 T CY 20211100666T CY 211100666 T CY211100666 T CY 211100666T CY 1124564 T1 CY1124564 T1 CY 1124564T1
- Authority
- CY
- Cyprus
- Prior art keywords
- infectiousness
- attenuated
- bacteria
- treatment
- solid tumors
- Prior art date
Links
- 230000002238 attenuated effect Effects 0.000 title abstract 2
- 241000894006 Bacteria Species 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0291—Yersinia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15195490 | 2015-11-19 | ||
| PCT/EP2016/078084 WO2017085233A1 (en) | 2015-11-19 | 2016-11-17 | Virulence attenuated bacteria for treatment of malignant solid tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124564T1 true CY1124564T1 (el) | 2022-07-22 |
Family
ID=54697464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100666T CY1124564T1 (el) | 2015-11-19 | 2021-07-22 | Εξασθενημενης λοιμογονικοτητας βακτηριδια για θεραπεια κακοηθων συμπαγων ογκων |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11166987B2 (enExample) |
| EP (2) | EP3377094B1 (enExample) |
| JP (1) | JP7060503B2 (enExample) |
| KR (1) | KR102736981B1 (enExample) |
| CN (1) | CN108472348B (enExample) |
| AU (1) | AU2016358257B2 (enExample) |
| BR (2) | BR112018009753B1 (enExample) |
| CA (1) | CA3003563A1 (enExample) |
| CY (1) | CY1124564T1 (enExample) |
| DK (1) | DK3377094T3 (enExample) |
| EA (1) | EA201890868A1 (enExample) |
| ES (1) | ES2880431T3 (enExample) |
| HR (1) | HRP20211191T1 (enExample) |
| HU (1) | HUE055132T2 (enExample) |
| IL (1) | IL259052B2 (enExample) |
| LT (1) | LT3377094T (enExample) |
| PL (1) | PL3377094T3 (enExample) |
| PT (1) | PT3377094T (enExample) |
| RS (1) | RS62152B1 (enExample) |
| SG (1) | SG11201803643TA (enExample) |
| SI (1) | SI3377094T1 (enExample) |
| SM (1) | SMT202100423T1 (enExample) |
| WO (1) | WO2017085233A1 (enExample) |
| ZA (1) | ZA201803902B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107001431B (zh) | 2014-05-21 | 2022-11-01 | 巴塞尔大学 | 基于细菌的蛋白质递送 |
| SMT202000620T1 (it) | 2015-11-19 | 2021-01-05 | Univ Basel | Distribuzione di proteine basata su batteri |
| JP6976351B2 (ja) | 2016-12-20 | 2021-12-08 | ウニヴェルズィテート・バーゼルUniversitat Basel | 弱毒化細菌に基づくタンパク質送達 |
| KR102110993B1 (ko) * | 2018-12-20 | 2020-05-14 | 한국생명공학연구원 | 클레브시엘라 아에로제네스(Klebsiella aerogenes) 균주를 유효성분으로 포함하는 암 진단, 예방 또는 치료용 조성물 |
| IL302334A (en) * | 2020-10-27 | 2023-06-01 | T3 Pharmaceuticals Ag | Providing bacteria-based protein |
| CN114712496B (zh) * | 2022-04-29 | 2023-10-13 | 中山大学·深圳 | 一种展示新抗原的细菌衍生外膜囊泡疫苗及制备方法和在制备癌症免疫治疗试剂盒中的应用 |
| CN116064877B (zh) * | 2023-02-09 | 2024-09-20 | 宁夏大学 | 利用lamp技术快速检测阴沟肠杆菌的试剂盒及方法 |
| CN116855496B (zh) * | 2023-07-05 | 2024-08-16 | 郑州大学 | 含有干扰序列siRNA-HIF-1α的表达质粒在制备抗肝细胞癌药物中的应用 |
| EP4761753A2 (en) * | 2023-08-17 | 2026-06-24 | Baccine Ltd. | Genetically modified bacteria for multi-modal secretion of a neoantigen |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965381A (en) | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
| US6596509B1 (en) | 1998-07-10 | 2003-07-22 | Cornell Research Foundation, Inc. | Recombinant constructs and systems for secretion of proteins via type III secretion systems |
| US20020160502A1 (en) | 2000-09-26 | 2002-10-31 | Roger Williams Hospital | Recombinant BCG vaccines for the prevention and treatment of cancer |
| AU2002312778A1 (en) | 2001-03-26 | 2002-10-08 | Universite Catholique De Louvain | Type iii bacterial strains for use in medicine |
| US8058442B2 (en) | 2002-11-07 | 2011-11-15 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| FR2862312B1 (fr) | 2003-11-13 | 2006-02-17 | Univ Grenoble 1 | Outil de transfert et de production de proteines mettant en oeuvre le systeme de secretion de type iii de pseudomonas |
| US8357373B2 (en) | 2005-10-04 | 2013-01-22 | Ludwig Institute For Cancer Research | Methods for stimulating an immune response using bacterial antigen delivery system |
| WO2008019183A2 (en) | 2006-05-18 | 2008-02-14 | The Regents Of The University Of California | Biopolymer and protein production using type iii secretion systems of gram negative bacteria |
| TW200819540A (en) * | 2006-07-11 | 2008-05-01 | Genelux Corp | Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders |
| EP2268313A2 (en) | 2008-03-17 | 2011-01-05 | Universitätsklinikum Münster | Yopm as delivery vehicle for cargo molecules and as biological therapeutic for immunomodulation of inflammatory reactions |
| EP2717886B1 (en) | 2011-06-08 | 2021-09-01 | Chelation Partners Incorporated | Metal chelating compositions and methods for controlling the growth or activities of a living cell or organism |
| US9127284B2 (en) * | 2012-05-04 | 2015-09-08 | The University Of Hong Kong | Modified bacteria and their uses thereof for the treatment of cancer or tumor |
| JP6936934B2 (ja) | 2013-09-24 | 2021-09-22 | メディシナ セラピューティクス インコーポレイテッド | インターロイキン−４受容体結合融合タンパク質及びその使用 |
| US10143743B2 (en) | 2013-11-18 | 2018-12-04 | Yale University | Non-replicating bacterial nanoparticle delivery system and methods of use |
| CN107001431B (zh) | 2014-05-21 | 2022-11-01 | 巴塞尔大学 | 基于细菌的蛋白质递送 |
| SMT202000620T1 (it) | 2015-11-19 | 2021-01-05 | Univ Basel | Distribuzione di proteine basata su batteri |
| JP6976351B2 (ja) | 2016-12-20 | 2021-12-08 | ウニヴェルズィテート・バーゼルUniversitat Basel | 弱毒化細菌に基づくタンパク質送達 |
-
2016
- 2016-11-17 EA EA201890868A patent/EA201890868A1/ru unknown
- 2016-11-17 DK DK16797930.1T patent/DK3377094T3/da active
- 2016-11-17 EP EP16797930.1A patent/EP3377094B1/en active Active
- 2016-11-17 RS RS20210926A patent/RS62152B1/sr unknown
- 2016-11-17 HR HRP20211191TT patent/HRP20211191T1/hr unknown
- 2016-11-17 KR KR1020187016568A patent/KR102736981B1/ko active Active
- 2016-11-17 SM SM20210423T patent/SMT202100423T1/it unknown
- 2016-11-17 SG SG11201803643TA patent/SG11201803643TA/en unknown
- 2016-11-17 ES ES16797930T patent/ES2880431T3/es active Active
- 2016-11-17 SI SI201631290T patent/SI3377094T1/sl unknown
- 2016-11-17 AU AU2016358257A patent/AU2016358257B2/en active Active
- 2016-11-17 EP EP21170509.0A patent/EP3903813A1/en active Pending
- 2016-11-17 JP JP2018526167A patent/JP7060503B2/ja active Active
- 2016-11-17 WO PCT/EP2016/078084 patent/WO2017085233A1/en not_active Ceased
- 2016-11-17 PL PL16797930T patent/PL3377094T3/pl unknown
- 2016-11-17 LT LTEP16797930.1T patent/LT3377094T/lt unknown
- 2016-11-17 US US15/773,524 patent/US11166987B2/en active Active
- 2016-11-17 BR BR112018009753-5A patent/BR112018009753B1/pt active IP Right Grant
- 2016-11-17 PT PT167979301T patent/PT3377094T/pt unknown
- 2016-11-17 IL IL259052A patent/IL259052B2/en unknown
- 2016-11-17 CN CN201680079454.XA patent/CN108472348B/zh active Active
- 2016-11-17 HU HUE16797930A patent/HUE055132T2/hu unknown
- 2016-11-17 CA CA3003563A patent/CA3003563A1/en active Pending
- 2016-11-17 BR BR122023024697-7A patent/BR122023024697A2/pt not_active Application Discontinuation
-
2018
- 2018-06-12 ZA ZA2018/03902A patent/ZA201803902B/en unknown
-
2021
- 2021-07-22 CY CY20211100666T patent/CY1124564T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124488T1 (el) | Απελευθερωση πρωτεϊνης που βασιζεται σε εξασθενημενης λοιμογονικοτητας βακτηριδια | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201890868A1 (ru) | Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей | |
| EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
| EA201790413A1 (ru) | Антитела против tigit | |
| TW201611847A (en) | Compounds and compositions for treating EGFR expressing tumors | |
| EP4691562A3 (en) | Anti-pd-l1 combinations for treating tumors | |
| EA201790173A1 (ru) | Антитела, связывающие axl | |
| EA201692100A1 (ru) | Новые антитела против rnf43 и способы их применения | |
| MX2020006297A (es) | Variantes de cd19. | |
| MX383034B (es) | Tratamiento de cáncer de pulmón con inhibidores de glutaminasa. | |
| EA201991818A1 (ru) | Лечение рака | |
| MA40458A (fr) | Méthodes de traitement du cancer du col de l'utérus | |
| TW201613587A (en) | Medical treatments based on anamorelin | |
| JOP20190190B1 (ar) | معالجة سرطان | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| BR112017009265A2 (pt) | apilimode para uso no tratamento do câncer colorretal | |
| EA201791249A1 (ru) | Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний | |
| MX2017000306A (es) | Metodos para tratar hipotension. | |
| MX2019011026A (es) | Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer. | |
| CY1124688T1 (el) | Θεραπεια πρωτεϊνουριας | |
| EA201790990A1 (ru) | Мультипептидный т-специфичный иммунотерапевтический препарат для лечения метастазов рака в головном мозге | |
| CO2017009182A2 (es) | Cepas bacterianas productoras de histamina para tratamiento del cáncer | |
| LT3405213T (lt) | Bakteriniai šešėliai, skirti panaudoti vėžio gydyme | |
| EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка |